G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
about
Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancerOvercoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune DysfunctionCancer-Associated Myeloid Regulatory CellsMyeloid cell signatures in tumor microenvironment predicts therapeutic response in cancerEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsCompensatory angiogenesis and tumor refractorinessVasculogenesis: a crucial player in the resistance of solid tumours to radiotherapyMyeloid-derived suppressor cells and anti-tumor T cells: a complex relationshipA role for G-CSF and GM-CSF in nonmyeloid cancersResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaRNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibEmerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasisMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedA PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancerDual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkersContribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceBST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer.Molecular mechanisms of resistance to tumour anti-angiogenic strategiesExpression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancerHuman adipose tissue-resident monocytes exhibit an endothelial-like phenotype and display angiogenic propertiesAll-trans-retinoic acid and the glycolipid α-galactosylceramide combined reduce breast tumor growth and lung metastasis in a 4T1 murine breast tumor model.Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR-106IL-35 induces N2 phenotype of neutrophils to promote tumor growth.Chemotherapy and tumor microenvironment of pancreatic cancer.Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancerEssential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.Targeting immune suppressing myeloid-derived suppressor cells in oncology.The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanismThe pre-metastatic niche: finding common ground.Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytesAngiogenesis - still a worthwhile target for breast cancer therapy?Antiangiogenic therapy for glioblastoma: current status and future prospects.Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13GRANULOCYTE INFILTRATION AND EXPRESSION OF THE PRO-ANGIOGENIC BV8 PROTEIN IN EXPERIMENTAL EL4 AND LEWIS LUNG CARCINOMA TUMORS.Molecular pathways: myeloid complicity in cancer.
P2860
Q26741623-0F62914E-5D2C-403C-8625-440467468A1AQ26749333-14C538D4-79CB-447F-9175-4D4A37B10CE1Q26750382-F1AF1DE3-A016-46C1-B710-E8C7EDF01B68Q26752838-31203239-1C44-451D-AD6B-75687D85066CQ26773795-1574F6BE-FF7B-40B8-B34C-9D71E7A0635FQ26851916-0D528DF5-4F67-42D3-8287-AAFF52DDF1E8Q26999217-8075EBD0-11BC-47FF-9B33-9223266FFCE5Q27000087-7AD96CA4-282F-495A-AC82-A780A04C730DQ27002515-016D4A89-38FD-4527-9C18-225A3D5188FCQ27016629-1353A0A2-1562-4CC0-8952-0972A4759095Q27021470-2EDD2EED-C73E-4C21-9DE5-78A70D627F72Q27315803-4932080C-581A-45B3-A6E3-51D82615D1D8Q28069422-00D0E7AA-20FF-4BF0-AF4B-DDFF2DE7BC84Q28084627-E700DADD-A969-4B36-AE64-39F5F9257BDCQ28485246-29C76E68-7631-4002-A790-87155C130F63Q33415397-CB5B7591-79AC-4AC8-8554-ED8109A34BDBQ33539387-51475762-5DAA-45AB-A6E2-758C2D931086Q33587106-72BFB95F-C8B4-4FE1-A84E-5176385BDE3AQ33627739-1825B1B0-F40A-449F-8C1F-D5B1DC91AABFQ33631179-EC5D6C62-2323-4039-AF5F-1C233CB20BC7Q33718025-5F7F9B7B-9178-4E4B-A0D4-306968F31542Q33745294-771132A3-32B9-4BBF-B732-07BFC285DC72Q33746428-AA6B633C-DCF3-448E-B4F5-55029893286DQ33769503-2CD6AF19-C250-4231-89AA-6B6E943B93D8Q33778236-F8BCADF9-E287-4228-A3E5-1B49FEAE63A6Q33779538-6C8E9F13-0BA1-443F-833E-5886A0E3DE7AQ33876637-029877BE-01A1-49CD-B694-DE2F4C72A3D0Q33888808-8E62D8F0-4231-4A7E-A787-395CBF696735Q34031959-6D593F72-A59E-4AF1-846E-CE43038AD615Q34081723-7327FD20-6B06-4D28-88B3-8994075D3AFDQ34082067-C3BBD479-6D23-48E8-A779-A91B1F8C31EEQ34134697-8BE60D6B-7F98-4982-B0B3-B426178C9EC0Q34213977-67F4A507-5F1D-4CBA-B67E-12A5AB8616F0Q34342357-B89F4417-BCE1-4A18-A448-ED4491353CFEQ34411361-C82BD853-9C33-490E-9FB0-DA4B5D25DB37Q34423550-5069FC8B-07B8-4A29-8DBF-982C87F6614BQ34523319-215EE72B-F53C-48D7-8026-7E9F60C8C851Q34541778-75F7B740-1A71-4B79-B571-BF72883F6ECCQ34646371-FE6C88EE-3FE8-4A64-BF8F-1B53C3870344Q34725969-062DE2C8-1BA8-4519-B3B9-AC61EE02F606
P2860
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@en
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@nl
type
label
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@en
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@nl
prefLabel
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@en
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@nl
P2093
P2860
P356
P1476
G-CSF-initiated myeloid cell m ...... -VEGF therapy in mouse models.
@en
P2093
Farbod Shojaei
Marcin Kowanetz
Martha Tan
Napoleone Ferrara
Xueping Qu
Y Gloria Meng
P2860
P304
P356
10.1073/PNAS.0902280106
P407
P577
2009-04-03T00:00:00Z